Drug repurposing for autism spectrum disorders has been hampered by the heterogeneity of the condition and limited understanding of how existing medications might target specific genetic variants. This breakthrough approach could accelerate therapeutic development by systematically matching FDA-approved compounds to distinct autism gene profiles.
Researchers created behavioral fingerprints for 520 FDA-approved drugs using zebrafish larvae, then cross-referenced these profiles against behavioral patterns from nine major autism genes including SCN2A and DYRK1A. The systematic screening revealed that estropipate (an estrogen receptor agonist) effectively suppressed abnormal behaviors in SCN2A mutants, while paclitaxel (a microtubule stabilizer) showed efficacy in DYRK1A variants. Most notably, levocarnitine, a mitochondrial metabolism enhancer already available as a dietary supplement, rescued behavioral deficits in both genetic models. Validation studies demonstrated that levocarnitine restored normal brain activity patterns and corrected disrupted lipid metabolism pathways in the mutant fish.
This precision medicine framework represents a significant methodological advance over traditional autism drug development, which typically employs broad behavioral interventions without genetic stratification. The identification of mitochondrial metabolism as a convergent therapeutic target across different autism genes aligns with emerging evidence of bioenergetic dysfunction in autism spectrum disorders. However, translating these zebrafish findings to human patients remains challenging, as the behavioral assays measure basic sensory processing rather than complex social and communication deficits that define clinical autism. The approach's real value may lie in rapidly identifying mechanistic pathways for further investigation rather than directly predicting clinical efficacy.